Endocrine Disrupting Chemicals and Endometrial Cancer: An Overview of Recent Laboratory Evidence and Epidemiological Studies.

Int J Environ Res Public Health

Surgical and Medical Department of Translational Medicine, Sant'Andrea Hospital, Faculty of Medicine and Psycology, University of Rome "Sapienza", Via di Grottarossa n° 1035, 00139 Rome, Italy.

Published: March 2017

: Although exposure to endocrine disruptor compounds (EDCs) has been suggested as a contributing factor to a range of women's health disorders including infertility, polycystic ovaries and the early onset of puberty, considerable challenges remain in attributing cause and effect on gynaecological cancer. Until recently, there were relatively few epidemiological studies examining the relationship between EDCs and endometrial cancer, however, in the last years the number of these studies has increased. : A systematic MEDLINE (PubMed) search was performed and relevant articles published in the last 23 years (from 1992 to 2016) were selected. : Human studies and animal experiments are confirming a carcinogenic effect due to the EDC exposure and its carcinogenesis process result to be complex, multifactorial and long standing, thus, it is extremely difficult to obtain the epidemiological proof of a carcinogenic effect of EDCs for the high number of confusing factors. : The carcinogenic effects of endocrine disruptors are plausible, although additional studies are needed to clarify their mechanisms and responsible entities. Neverthless, to reduce endocrine disruptors (ED) exposure is mandatory to implement necessary measures to limit exposure, particularly during those periods of life most vulnerable to the impact of oncogenic environmental causes, such as embryonic period and puberty.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369169PMC
http://dx.doi.org/10.3390/ijerph14030334DOI Listing

Publication Analysis

Top Keywords

endometrial cancer
8
epidemiological studies
8
endocrine disruptors
8
studies
5
endocrine
4
endocrine disrupting
4
disrupting chemicals
4
chemicals endometrial
4
cancer overview
4
overview laboratory
4

Similar Publications

Introduction: To identify prognostic biomarkers that could predict how well patients will respond to lenvatinib/pembrolizumab (LEN/PEM). The utility of certain inflammatory biomarkers in endometrial liquid-based cytology (LBC) or peripheral blood samples, such as neutrophil counts, lymphocyte counts, and neutrophil-to-lymphocyte ratio (NLR) were explored.

Methods: The study included 25 patients with advanced or recurrent endometrial cancer who had received LEN/PEM between August 2018 and March 2024.

View Article and Find Full Text PDF

Endometrial cancer (EC) diagnosis traditionally relies on tumor morphology and nuclear grade, but personalized therapy demands a deeper understanding of tumor mutational burden (TMB), i.e., a key biomarker for immune checkpoint inhibition and immunotherapy response.

View Article and Find Full Text PDF

Perfluorobutanoic acid: A short-chain perfluoroalkyl substance exhibiting estrogenic effects through the estrogen-related receptor γ pathways.

J Hazard Mater

December 2024

College of Energy Environment and Safety Engineering, China Jiliang University, 258 Xueyuan Street, Hangzhou, Zhejiang 310018, China; Institute of Environmental and Health Sciences, China Jiliang University, 168 Xueyuan Street, Hangzhou, Zhejiang 310018, China. Electronic address:

Perfluorobutanoic acid (PFBA) is an emerging contaminant that was demonstrated to exhibit estrogen effects via action on classic estrogen receptors (ERs) in a low-activity manner. The purpose of the present study is to reveal the estrogen disruption effect and mechanism of PFBA via estrogen-related receptor γ (ERRγ) pathways. In vivo experiment indicated that PFBA accumulated in zebrafish ovary and caused ovarian injury, with disturbing sex hormone levels and interfering gene expression related to estrogen synthesis and follicle regulation.

View Article and Find Full Text PDF

MAPK14/p38α shapes the molecular landscape of endometrial cancer and promotes tumorigenic characteristics.

Cell Rep

December 2024

Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA; Curriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill, NC 27599, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA. Electronic address:

The molecular underpinnings of high-grade endometrial carcinoma (HGEC) metastatic growth and survival are poorly understood. Here, we show that ascites-derived and primary tumor HGEC cell lines in 3D spheroid culture faithfully recapitulate key features of malignant peritoneal effusion and exhibit fundamentally distinct transcriptomic, proteomic, and metabolomic landscapes compared with conventional 2D monolayers. Using a genetic screening platform, we identify MAPK14 (which encodes the protein kinase p38α) as a specific requirement for HGEC in spheroid culture.

View Article and Find Full Text PDF

Robotic dual-docking surgery for para-aortic lymphadenectomy in endometrial cancer: a prospective feasibility study.

Int J Clin Oncol

December 2024

Department of Obstetrics & Gynecology, Faculty of Medicine, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan.

Background: The standard for robotic para-aortic lymphadenectomy has not been fully established. Para-aortic lymphadenectomy performed by sharing the same ports with pelvic procedures, a procedure known as dual-docking surgery, can be performed using the latest robotic system. We prospectively examined the ability of standardized dual-docking robotic surgery in endometrial cancer patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!